Skip to main content
LUSHANG FREDA PHARMACEUTICAL CO.,LTD. logo

LUSHANG FREDA PHARMACEUTICAL CO.,LTD. — Investor Relations & Filings

Ticker · 600223 ISIN · CNE000001147 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,828 across all filing types
Latest filing 2026-05-26 AGM Information
Country CN China
Listing Shanghai Stock Exchange 600223

About LUSHANG FREDA PHARMACEUTICAL CO.,LTD.

http://www.lshfreda.com/

Lushang Freda Pharmaceutical Co., Ltd. specializes in the research, development, and manufacturing of pharmaceutical products, health supplements, and high-end cosmetics. The company is recognized as a global leader in the production of sodium hyaluronate (hyaluronic acid), utilizing advanced fermentation technology to supply raw materials for medical, food, and cosmetic applications. Its product portfolio spans several therapeutic areas, including ophthalmology, orthopedics, and dermatology, with a significant focus on medical aesthetics and functional skincare. By integrating biotechnology with industrial-scale production, the company maintains a comprehensive supply chain that supports both its proprietary brands and international B2B partnerships. Key operations involve the synthesis of bioactive substances and the formulation of specialized treatments designed to improve skin health and joint mobility.

Recent filings

Filing Released Lang Actions
鲁商福瑞达医药股份有限公司关于召开2025年年度股东会的通知
AGM Information Classification · 92% confidence The document is a detailed notice (“关于召开2025年年度股东会的通知”) issued by the board of directors calling the 2025 Annual General Meeting (AGM), listing the meeting date, location, voting procedures, agenda items, participation requirements, proxy form and attachments. It does not contain financial statements or results, nor is it merely a brief publication announcement. Therefore it is classified as AGM Information.
2026-05-26 Chinese
鲁商福瑞达医药股份有限公司第十二届董事会2026年第一次临时会议决议公告
Regulatory Filings Classification · 73% confidence The document is a formal announcement of resolutions passed at the company’s 12th Board of Directors Extraordinary Meeting. It does not present financial statements (so it is not an Annual or Interim Report), nor does it certify or attach any report (so it is not a Report Publication Announcement). It is not detailing a change in board composition (so it is not MANG), nor shareholder votes (DVA), dividends (DIV), or any financial data. It is a regulatory announcement of board resolutions, fitting the catch-all Regulatory Filings category (RNS).
2026-05-26 Chinese
鲁商福瑞达医药股份有限公司董事和高级管理人员薪酬管理制度
Remuneration Information Classification · 89% confidence The document is a formal policy titled “董事和高级管理人员薪酬管理制度,” detailing the company’s remuneration principles, structure, governance, and procedures for directors and senior management. It does not present financial statements or vote results, nor is it a meeting presentation, but specifically outlines compensation arrangements for top executives. This fits the “Remuneration Information (Code: DEF 14A)” category.
2026-05-26 Chinese
鲁商福瑞达医药股份有限公司2025年年度股东会会议资料
AGM Information Classification · 92% confidence The document is clearly titled “2025年年度股东会会议资料” (“2025 Annual Shareholders’ Meeting Materials”) and contains agenda items (board work report, profit distribution plan, remuneration proposals, guarantees, financial service agreements, etc.) to be presented and voted at the 2025 Annual General Meeting. This is not the full annual report or financial statements but the meeting materials for the AGM. According to our definitions, this falls under AGM Information (AGM-R).
2026-05-26 Chinese
鲁商福瑞达医药股份有限公司关于召开2026年第一季度业绩说明会的公告
Regulatory Filings Classification · 85% confidence The document is a formal announcement to convene a first quarter performance explanation meeting (业绩说明会) for Q1 2026. It does not contain financial statements, slides, or actual earnings data, nor is it the earnings release itself. It simply notifies investors of an upcoming online Q&A session. There is no specific category for an earnings call notice, so it falls under general regulatory announcements (RNS).
2026-05-26 Chinese
鲁商福瑞达医药股份有限公司2025年度“提质增效重回报”行动方案的评估报告暨2026年度“提质增效重回报”行动方案
Management Reports Classification · 95% confidence The document is an evaluation report and action plan related to the company's quality improvement and efficiency enhancement initiatives for the years 2025 and 2026. It includes detailed descriptions of business strategies, financial performance, R&D activities, dividend policies, investor communication, governance improvements, and compliance efforts. The document is issued by the company's board and is presented as an official announcement. It is not a full annual report or interim financial report, nor is it a simple announcement of a report publication. The content focuses on operational plans, performance evaluation, and forward-looking strategies rather than purely financial statements or regulatory certifications. Given the detailed nature of the report and its focus on management's explanation of business trends, performance, and outlook, it fits best under the category of Management Reports (MDA). The document length is under 5,000 characters but contains substantive content beyond a mere announcement, so it is not an RPA. Therefore, the classification is MDA with high confidence.
2026-04-02 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.